Search

Displaying results 1301 - 1310 of 10000 in total
  1. Drug

    VidPrevtyn Beta

    go.drugbank.com/drugs/DB16427
    Approved

    [L49691] It comprises a recombinant SARS-CoV-2 spike protein (B.1.351 strain) - produced by recombinant DNA technology using a baculovirus expression system in an insect cell line that is derived from … [A245829,L49696] In October 2022, VidPrevtyn Beta was approved in the European Union for use as a booster dose in patients who have previously received a COVID-19 vaccine.[L49691]

  2. Drug

    Alirocumab

    go.drugbank.com/drugs/DB09302
    ApprovedInvestigational

    Alirocumab is a biopharmaceutical that obtained FDA approval in July 2015 as a second line treatment for high cholesterol in adults whose LDL-cholesterol (LDL-C) is not controlled by the combination of … It is a human monoclonal antibody part of the family of the PCSK9 inhibitors which are a novel class of anticholesterol therapeutics. From this family, it was the first agent to receive FDA approval.

    Products: PRALUENT 150 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN), PRALUENT 75 MG/ML (SOLUTION FOR INJECTION IN PRE-FILLED PEN)
  3. Drug

    Nebicapone

    go.drugbank.com/drugs/DB14849
    Investigational

    Nebicapone is under investigation in clinical trial NCT03097211 (Effect of BIA 6-512 at Steady-state on the Levodopa Pharmacokinetics With a Single-dose of Levodopa/Benserazide 200/50 mg or With a Single-dose … of Levodopa/Benserazide 200/50 mg Plus a Single-dose of Nebicapone 150 mg).

  4. Drug

    Vandetanib

    go.drugbank.com/drugs/DB05294
    ApprovedInvestigational

    On April 6 2011, vandetanib was approved by the FDA to treat nonresectable, locally advanced, or metastatic medullary thyroid cancer in adult patients. … Vandetanib is an oral once-daily kinase inhibitor of tumour angiogenesis and tumour cell proliferation with the potential for use in a broad range of tumour types.

    Synonyms: N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methyl-4-piperidinyl)methoxy)-4-quinazolinamine, N-(4-Bromo-2-fluorophenyl)-6-methoxy-7-((1-methylpiperidin-4-yl)methoxy)quinazolin-4-amine
  5. Drug

    Propiolactone

    go.drugbank.com/drugs/DB09348
    ApprovedWithdrawn

    It has been used against bacteria, fungi, and virus.[A32144] It is currently FDA approved for its use as an indirect additive used in food contact substances. … Propiolactone was first commercially available in the United States in 1958.[A32144]

    Categories: Compounds used in a research, industrial, or household setting
  6. Drug

    Bronopol

    go.drugbank.com/drugs/DB13960
    Approved

    The agent is largely available commercially as an antibacterial for a variety of industrial purposes while it is predominantly available for purchase as a pet animal litter antibacterial at the domestic … L4873] and in other products where it may not primarily be used in the role of a non-medicinal preservative antimicrobial [L4874].

    Mixtures: Disinfectant Wet Wipes, Antibacterial Wet WipesCategories: Compounds used in a research, industrial, or household setting
  7. Drug

    Durvalumab

    go.drugbank.com/drugs/DB11714
    ApprovedInvestigational

    small cell lung cancer (ES-SCLC). … [A192789,L12627] On March 27, 2020, durvalumab was approved by the FDA for use in combination with [etoposide] and either [carboplatin] or [cisplatin] as first-line treatment of patients with extensive-stage

    Products: IMFINZI CONCENTRATE FOR SOLUTION FOR INFUSION 50 MG/ML, IMFINZI® 50 MG/ML CONCENTRADO PARA SOLUCIÓN PARA INFUSIÓN
  8. Drug

    Rozibafusp Alfa

    go.drugbank.com/drugs/DB19233
    Investigational

    Rozibafusp Alfa is under investigation in clinical trial NCT04058028 (Efficacy and Safety of AMG 570 in Subjects With Active Systemic Lupus Erythematosus (SLE)).

  9. Drug

    Enzalutamide

    go.drugbank.com/drugs/DB08899
    ApprovedInvestigational

    [L40639] It is a second-generation antiandrogen agent that the FDA approved on August 31, 2012. … [L40639, A252667] Although androgen deprivation therapy (ADT) is the first-line treatment of prostate cancer and remission can be achieved, arising resistance is inevitable, becoming castration-resistant

    Products: XTANDI 40 MG, XTANDI ® 40 MG
  10. Drug

    Zolbetuximab

    go.drugbank.com/drugs/DB15118
    ApprovedInvestigational

    [L51923] It is specifically targeted against CLDN18.2, a membrane protein normally found in gastric mucosal cells which is overexpressed in 30-50% of gastric and gastroesophageal junction (GEJ) adenocarcinomas … [A264723] Zolbetuximab was approved by the FDA in October 2024 for use in patients with HER2 negative, CLDN18.2-positive gastric and GEJ adenocarcinomas.[L51943,L51923]